Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
24 Feb, 20:00
NYSE NYSE
$
246. 28
+0.44
+0.18%
$
584.38B Market Cap
29.06 P/E Ratio
1.34% Div Yield
7,236,282 Volume
9.91 Eps
$ 245.84
Previous Close
Day Range
244.55 247.25
Year Range
141.5 247.25
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
JNJ earnings report is expected in 47 days (13 Apr 2026)
Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know

Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know

Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.

Zacks | 1 month ago
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 1 month ago
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve

J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve

JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Zacks | 1 month ago
Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said.

Wsj | 1 month ago
Johnson & Johnson reaches deal with US government to lower drug prices

Johnson & Johnson reaches deal with US government to lower drug prices

Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs.

Reuters | 1 month ago
J&J's Innovative Medicine Segment in Q4: Here's What to Watch

J&J's Innovative Medicine Segment in Q4: Here's What to Watch

JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.

Zacks | 1 month ago
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus

JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus

J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.

Zacks | 1 month ago
JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?

JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?

J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.

Zacks | 1 month ago
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from the preceding trading day.

Zacks | 1 month ago
Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?

Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 1 month ago
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 month ago
Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

CNBC's "Mad Money" host is waving the yellow flag.

Investopedia | 1 month ago
Loading...
Load More